The application period is now open for all who wish to participate in the ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program at Prevent Blindness. Individuals with vision impairment or blindness are welcome to participate, as well as allies (i.e. parents or guardians, care partners, nonprofit representatives, multidisciplinary clinicians, eye care providers, [Read More]
Category: Latest News
Free Updated “GuideMe” Book for AMD Now Online
Similar to a practicing low vision therapist, the GuideMe Book for age-related macular degeneration gathers personal information from the client, then offers guidance and resources unique to the client’s personal needs and goals. Prevent Blindness, a patient advocacy organization preserving vision and eye health for more than 115 years, continues to give the gift of [Read More]
Important New Survey Identifies Impact of Blindness and Low Vision on Senior Adults
Big data reports for each U.S state are now available from the survey. VisionServe Alliance and The Ohio State University College of Optometry have completed an important national project to comprehensively describe Americans ages 65 and older who are blind or have low vision. The data sets analyzed are from the CDC’s Behavioral Risk [Read More]
FDA Approval Brings Long Awaited Hope to Patients With Geographic Atrophy
by Jeff Todd, President + CEO at Prevent Blindness And just like that, the landscape for vision loss and blindness has shifted dramatically! For years, millions of people around the world who are living with an untreatable and potentially blinding condition, along with their care partners, have been waiting with hopeful anticipation for a treatment [Read More]
First Treatment For Geographic Atrophy Approved
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Visual Impairment in Senior Adults Apellis Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved SYFOVRE™ (pegcetacoplan injection) 15mg/0.1mL, the first and only treatment for geographic atrophy (GA) secondary to age-related [Read More]